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REVIEWAppropriate antimicrobial therapy in the era of multidrug-resistant human
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Medicine, Tel-Aviv University, Tel-Aviv, IsraelAbstractThe past decade has brought a signiﬁcant rise in antimicrobial resistance, and the ESKAPE pathogens have become a signiﬁcant threat to public
health. Three epidemiological features that negatively impact patients, which are consistently seen with the ESKAPE pathogens, are the
following: 1) there has been a rise in incidence of these organisms as causative human pathogens, 2) there has been a signiﬁcant increase
in antimicrobial resistance in these bacterial species, and 3) the infections caused by these resistant strains are associated with worse
outcomes when compared with infections caused by their susceptible counterparts. Signiﬁcant delays in time to appropriate antimicrobial
therapy of up to 5 days have been reported in infections due to these organisms and this is the strongest predictor of mortality with
ESKAPE pathogens, particular in critically ill patients, where every hour delay has an incremental survival disadvantage for patients.
Strategies to decrease these delays are urgently needed. Although routine broad-spectrum empiric coverage for these organisms would
ideally limit this delay, agents with activity against these organisms are sometimes less effective, have signiﬁcant toxicity risk, and their use
can result in the development of resistance. Therefore, strategies to optimize therapy, although limiting unnecessary use of broad-
spectrum antimicrobials, are urgently needed. This review will discuss potential strategies to optimize empiric therapy in the age of multi-
drug resistance, the limitations of these strategies, and will discuss future directions and opportunities.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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In 2009, the Infectious Diseases Society of America published a
position paper that expressed the urgent, immediate need for
development of new agents with activity against multidrug-
resistant (MDR), extensively drug-resistant (XDR) and pan-
drug-resistant (PDR) organisms [1,2]. Certain MDR, XDR and
PDR organisms (to be referred to collectively as MDROs), inMicrobiol Infect 2015; 21: 302–312
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.12.025certain regions, have become prevalent pathogens [3], and
some have successfully spread to community settings as well
[4–11]. The Infectious Diseases Society of America formulated
an acronym ESKAPE, in order to emphasize the group of
pathogens that cause hospital infections and effectively ‘escape’
the effects of antibacterial drugs. These include the Gram-
positive organisms vancomycin-resistant enterococci (VRE)
and methicillin-resistant Staphylococcus aureus (MRSA); and the
Gram-negative pathogens Pseudomonas aeruginosa, Acinetobacter
baumannii, and extended spectrum β-lactamase producing
(ESBL) or carbapenem-resistant enterobacteriaceae (CRE) [1].
This paper will review the role and challenges associated with
appropriate antimicrobial therapy and its potential impact on
the epidemiology, management and outcomes of infections
caused by ESKAPE pathogens.ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Pogue et al. Appropriate therapy in the era of MDROs 303There are three important epidemiological features that are
common among infections caused by the ESKAPE pathogens: 1)
there has been a signiﬁcant increase in their overall incidence as
causative human pathogens, 2) there has been a signiﬁcant in-
crease in the rates of resistance to clinically applicable antimi-
crobial agents among these bacterial species, and 3) there are
devastating outcomes associated with these infections
compared with infections caused by susceptible strains of these
same bacterial species. Table 1 summarizes these ﬁndings for
each ESKAPE pathogen.Appropriate antimicrobial therapy and
clinical outcomes of ESKAPE pathogensThe fact that infections caused by the resistant strains of the
ESKAPE bacteria are signiﬁcantly and universally associated with
worse clinical outcomes, compared with their susceptible
counterparts, could lead to an assumption that resistant strains
might possess increased ‘virulence’ properties [12], or might
possess other epidemiological features that explain their asso-
ciation with worse outcomes [13]. However, poor outcomes
are probably due in large part to delays in implementation of
effective antimicrobial therapy. In many cases of ESKAPE-
associated infections, patients with these resistant organisms
suffer from prolonged delays in instituting appropriate antimi-
crobial therapy (i.e. DAAT), and in most analyses, DAAT was a
stronger independent predictor for poor outcomes than the
resistance determinant itself [13]. This is not a surprising ﬁnding
because DAAT is a well-known, strong, independent predictor
of poor outcome in septic patients [14]. In a detailed systematic
review, including 70 trials, inappropriate empirical antibiotic
treatment was associated with signiﬁcantly higher mortality
among patients with sepsis [15]. Table 2 summarizes relevant
data for ESKAPE pathogens on the impact that antimicrobial
resistance had on DAAT, and the subsequent impact the delays
in therapy had on clinical outcomes. Kumar et al. reported that
in septic shock, each hour of DAAT reduces survival rates by
7.6% [16]. Therefore, aggressive strategies to decrease DAAT
in infections, including those due to ESKAPE organisms, are
clinically warranted. Importantly, only for ESBL-producing or-
ganisms has the resistant determinant itself, in addition to
DAAT, been shown to be independently associated with worst
outcomes [12,17].
Concerns with overuse of broad-spectrum empiric
antibiotics
To minimize DAAT, one strategy would be to routinely pre-
scribe empiric antimicrobial therapy that is broad-spectrum in
nature. Unfortunately, empiric broad-spectrum antimicrobialClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyexposure does not come without risks. One well-described
example is related to vancomycin use and MRSA infections.
With the rise in the incidence of MRSA, empiric coverage with
vancomycin has become the standard of care for many
healthcare-associated infections. Johnson et al. reported that
vancomycin use had more than doubled over a 2-year period,
and that 60% of orders were inappropriate, largely because of
inappropriate empirical use in disease states where vancomycin
was not warranted or inappropriately continued, despite
microbiological results suggesting that β-lactam therapy was
preferred [18]. Not surprisingly, reports associating vancomy-
cin usage with acquisitions of VRE [19,20] and MRSA with
elevated vancomycin MIC have since followed [21]. Addition-
ally, vancomycin use, whether appropriate or not, has been
associated with signiﬁcant nephrotoxicity, and is not as effective
as β-lactams for infections resulting from susceptible organisms
[22]. Alternative therapies such as linezolid or daptomycin, if
overused, can also promote resistance [23–25].
With the previously described increase in drug resistance of
many Gram-negative pathogens [26–29], empiric double Gram-
negative coverage is recommended for critically ill patients with
nosocomial infections, in an attempt to provide coverage for
the infecting pathogen [30–32]. Although this type of strategy is
essential to improve patient outcomes as described above,
inappropriate application of this principle can lead to unnec-
essary exposure to broad-spectrum antimicrobials which could
lead to further development of resistance, increased rates of
toxicity and ultimately to poor outcomes [30]. These fears are
well founded as data have shown the association between
carbapenem use and carbapenem-resistant P. aeruginosa [28,33],
A. baumannii [34,35] and enterobacteriaceae [36–38], and
alarmingly, associations between polymyxin and tigecycline use
and resistance to these agents [39,40]. The consequences of
resistance to these agents are catastrophic, if resistance be-
comes widespread, and would essentially return us, in some
cases, to the pre-antibiotic era when managing PDR and XDR
infections. Therefore, it is essential that strategies are devel-
oped and used to optimize empiric coverage for these organ-
isms in the appropriate patients, while limiting or minimizing
exposure to broad-spectrum antimicrobials in patients who do
not necessitate these regimens.Strategies to optimize appropriate empiric
therapyPrediction scores
Pathogen-speciﬁc scores. Prediction scores to identify patients
at risk for target resistant organisms and therefore appropriate
patients and clinical scenarios for institution of broad-spectrumand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 302–312
TABLE 1. Select data showing epidemiological features of ESKAPE-associated infections
VRE MRSA ESBL CRE Acinetobacter baumannii Pseudomonas aeruginosa
Increase in incidence Rates of VR Enterococcus faecalis
increased from 0.72/1000
patient-days in 2003 to 1.68/
1000 patient-days in 2009
(p < 0.0001) [65]
In > 40 US children’s hospitals,
incidence increased from 6.7/
1000 admissions in 2002 to
21.1/1000 admissions in 2007
(p for trend 0.02) [66]
From 2004 to 2010, the
proportion of ESBL-
producing causing hospital-
acquired Escherichia coli
bacteraemia rose from 10/30
(33%) to 51/99 (51%)
(p 0.005) [52,67]
In 25 US community hospitals,
incidence increased from
0.26/100 000 patient-days in
2008 to 1.4/100 000 patient-
days in 2012 (p 0.01) [68]
From 2003 to 2008, at Detroit
Medical Center, incidence
had increased from 1.7/1000
patient days to 3.7/1000
patient days (p < 0.001) [29]
From 1997 to 2004, incidence
had increased from 0.26/1000
admissions to 0.7/1000
admissions (p 0.01) [52]
Increase in rates of resistance Resistance to vancomycin
among Enterococcus faecium
and Enterococcus faecalis had
increased from 20.3% in 2006
to 24.8% in 2009, and from
7.4% in 2005 to 13.1% in
2009, respectively [65]
Rates of MRSA resulting in
device-related infections
reported to the CDC
increased from 51% of all
Staphylococcus aureus in 2003
[69] to 56.2% reported in
2008 [70] (p < 0.01)
45% of K. pneumoniae and 35%
of Escherichia coli causing
hospital-acquired bacteraemia
were ESBL-producers [12,52]
CDC surveillance data show
rates of resistance to
carbapenems among Klebsiella
species had increased from
1.6% in 2001 to 10.4% in
2011 [71]
Resistance to both A/S and
imipenem increased from
10% to 60% from 2003 to
2008 [29]
Resistance to imipenem
increased from 13% in 1989
to 20% in 2006 in two US
centres (p for trend <0.001)
[28]
Worse outcomes compared to
susceptible bacteria of the
same species
Outcomes of VRE (93 patients)
vs. VSE (101 patients): Crude
mortality 48.4% vs. 26.7%,
length of hospital stay from
infection to discharge: 25 days
vs. 22 days, days in ICU: 17
days vs. 13 days [72]
MRSA infections independently
associated with increased
length of hospitalization
(p 0.02) and total hospital
charges (p 0.02) [73]. In a
meta-analysis of 31 studies
including 3963 patients, a
signiﬁcant increase in
mortality was associated with
MRSA BSI relative to MSSA
BSI (OR 1.93; p < 0.001) [74]
In a meta-analysis, including 16
studies, the crude RRs
demonstrated signiﬁcantly
increased mortality in ESBL-
associated BSI, compared to
susceptible
Enterobacteriaceae strains
(pooled RR = 1.85, p < 0.001)
[17]
Outcomes of CRE (48 patients)
vs. CSE (56 patients): Crude
mortality 44% vs. 12.5% [75]
Patients with isolates resistant
to carbapenems and to A/S
had increased mortality (43%
vs. 20%; p 0.01) [76]
Infection with MDR
P. aeruginosa strain was
associated with increased
mortality (OR = 4.4, p 0.04)
and LOS (HR = 2, p 0.001)
[77]
Notes Most VRE are Enterococcus
faecium, but as stated above,
rates are rising in Enterococcus
faecalis as well
Additional important features
are creeping MICs to
vancomycin which leads to
questionable efﬁcacy [22],
and the wide spread of
certain clones to community
setting [78]
Endemic in some community
settings worldwide [46,79]
Pipeline for A. baumannii
particularly dry
Abbreviations: A/S, ampicillin/sulbactam; BSI, bloodstream infection; CRE, carbapenem-resistant Enterobacteriaceae; CSE, carbapenem-susceptible Enterobacteriaceae; ESBL, extended-spectrum β-lactamase producing Enterobacteriaceae;
ESKAPE, an acronym displaying groups of multidrug resistant organisms set by the Infectious Diseases Society of America [1]; HR, hazard ratio; ICU, intensive care unit; LOS, length of hospital stay; MDR, multidrug resistant; MRSA, methicillin-
resistant Staphylococcus aureus; OR, odds ratio; RR, relative risk; VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci.
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyempiric antimicrobial therapy would be very useful to clinicians.
Such scores would help to minimize use of these sometimes
toxic and less effective agents in patients who are not at high
risk for resistant pathogens and could theoretically improve
patient outcomes, limit toxicity and mitigate the spread of
resistance [41,42]. Despite these theoretical advantages, there
has not yet been a single prediction score for treatment of
ESKAPE pathogens that has been widely used and become well
established. Prediction scores, to be successful, should be
simple, and consist of parameters that can easily be deduced at
the patient’s bedside during an initial clinical encounter.
A few prediction scores for ESKAPE pathogens have been
developed. Table 3 highlights some of the key ﬁndings from
these studies. Each score was focused on a speciﬁc clinical
indication for an individual pathogen. However, because of the
following limitations, none of the individual prediction scores
had sufﬁcient validity and have not been routinely used.
One major limitation of prediction scores is that risk factors
are shared among many different ESKAPE pathogens; and be-
tween ESKAPE pathogens and sepsis in general. For example,
previous antimicrobial use, healthcare exposure and dependent
functional status are risk factors not only for VRE, but also for
CRE and for sepsis acquired in intensive care units (ICUs) in
general [1,43]. Therefore, the value of a speciﬁed prediction
score is limited. To further complicate matters, the epidemi-
ology of MDROs is complex and continually evolving. The same
type of organism with various degrees of resistance might have
distinct epidemiological characteristics. For example, in many
ICUs, nosocomial sepsis might result from VRE, CRE,
carbapenem-resistant A. baumannii, or carbapenem-resistant
P. aeruginosa (i.e. usually XDR pathogens), but could also
result from MDR pathogens of the same species (i.e. ampicillin-
resistant vancomycin-susceptible enterococci, ESBL-producing
Enterobacteriaceae, carbapenem-susceptible A. baumannii or
carbapenem-susceptible P. aeruginosa) [3]. Another challenge is
that community pathogens are more frequently becoming
phenotypically MDR. In many regions around the world, pa-
tients with community-acquired infections (even without
healthcare-associated exposures) could present with MRSA or
ESBL infections [10,44–46].
A challenge in developing reliable scores for MDR and XDR
infections, relates also to methodological issues [47]. Most
studies to date have used the ESKAPE pathogens as ‘cases’, and
their susceptible counterparts as ‘controls’ (e.g. MRSA versus
methicillin-susceptible S. aureus (MSSA), ESBLs versus suscep-
tible Enterobacteriaceae). However, patients with MSSA in-
fections are typically not the ‘source population’ from which
the MRSA cases arise [48]. More complex study designs, such as
the matched case–case–control design are often more
appropriate and necessary [48,49]. Developing such scores toand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 302–312
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdifferentiate MDROs from XDROs (for example, ESBLs from
CRE) is methodologically very complex, in part, because the
epidemiological features of ESKAPE-MDROs are often similar
to ESKAPE-XDROs [42,47,50].
Disease state scores. In the course of acute sepsis, there are
mainly two points in time where the majority of misuse of
antimicrobials and DAAT occur, where speciﬁed prediction
scores (‘global scores’, not ‘pathogen-unique’ scores) might
have a role in improving patients’ outcomes: 1) the ‘MDR upon
admission score’, which might prompt clinicians to use broad-
spectrum antimicrobials such as carbapenems; and 2) the
‘nosocomial XDR score’, which might prompt clinicians to
consider use of drugs such as polymyxins. To our knowledge,
there are currently no effective scores available for either
scenario [42].
In many hospitals, the empiric coverage for community-
acquired infections presenting to acute-care emergency
rooms, particularly when no healthcare-associated exposures
are documented, will include broad-spectrum agents (e.g. a
third-generation cephalosporin), but will not include routine
coverage for MDROs such as ESBLs or MRSA [12,51]. There-
fore, the ‘MDR upon admission score’ should target pathogens
such as MRSA and ESBLs, depending on suspected source of
infection. In nosocomial sepsis, or patients with sepsis upon
admission but with recent healthcare exposures, many empiric
regimens at hospitals will include broad-spectrum antibiotics
with anti-pseudomonal and anti-MRSA activity, but will not
routinely include coverage for XDR pathogens such as VRE,
CRE, carbapenem-resistant A. baumannii or carbapenem-
resistant P. aeruginosa [42]. Therefore, the ‘nosocomial XDR
score’ should capture XDR pathogens, but not MDR pathogens.
The lack of a differentiating score is one of the primary drivers
for the high frequency of DAAT among ESKAPE-associated
sepsis, and such scores could mitigate this delay, while
limiting broad-spectrum and potentially toxic therapy to others.
Currently available prediction scores, due to their non-speciﬁc
nature, fail to fully address this issue [15]. Additionally, from a
practicality standpoint, empowering clinicians to use scores
such as these at the bedside could be difﬁcult.
Risk proﬁling
In the absence of prediction scores for varying degrees of resis-
tance among ESKAPE pathogens, clinicians often use risk proﬁling
in an attempt to reduce DAAT among patients with suspected
ESKAPE-associated infection. In many facilities, patients with
nosocomial sepsis, patients with healthcare-associated commu-
nity-onset infection, patients with certain risk factors (e.g. recent
antimicrobial treatment, long-term care facility residence, pres-
ence of foreign chronic invasive devices), or patients with
increased severity of the acute infection (i.e. septic shock orious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 302–312
CMI Pogue et al. Appropriate therapy in the era of MDROs 307multi-organ failure) will be treated empirically with broad-
spectrum antibiotics, often including anti-pseudomonal and/or
anti-MRSA coverage [52]. Although theoretically risk proﬁling
could reduce DAAT and improve patient outcomes, patients
with ESKAPE-associated infections, as described previously,
frequently share similar epidemiological characteristics [50]. In
many analyses, predictors of individual ESKAPE infections
demonstrated that these groups of pathogens affect somewhat
similar populations [3,11,50]. Table 4 highlights some of these
studies. Many prescribers feel that they have a good sense of the
local epidemiology in which they practice, but the fact that, in
many analyses, patients with ESKAPE infections still suffer from
frequent and prolonged DAAT indicates that risk proﬁling in its
non-standardized current form is a non-useful measure of
reducing DAAT.
One way that risk proﬁling has been used is to consider the
severity of a patient’s illness and the risk of not providing
effective empiric antimicrobial therapy (i.e. risk of getting
empiric therapy wrong). For example, for a stable patient, for
whom an MDR pathogen is unlikely, but possible, then a
reasonable option is to withhold broad-spectrum antimicrobials
that would cover MDR pathogens, so as to minimize toxicity,
potentially inferior therapy, and promotion of antimicrobial
resistance. If the same patient is septic and unstable, even if they
are at low risk for an MDR pathogen, many clinicians should
consider providing adequate coverage, knowing that if they do
not and the pathogen is MDR, the patient might die. The same
type of proﬁling should also occur in the ICU pertaining to the
risk for XDR pathogens and use of agents like the polymyxins.
Regardless, appropriate diagnostic and microbiological workup
should be performed with rapid escalation, de-escalation and/or
discontinuation when appropriate.
Combination antibiograms
Combination antibiograms offer powerful tools to optimize
empiric therapy within an ICU where time to appropriateTABLE 4. Examples of various matched cased-case-control analyse
Risk factor VRE [91,92] MRSA [93,94] ESB
Long-term care facility X
Recent exposure to antimicrobials X X X
Dependent functional status
Foreign invasive chronic devices
Recent surgery or invasive procedure
Recent prior hospitalization
Advanced age X X
Complex comorbidities X
Immunosuppressive states X
ICU stay X
Male sex X
Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-
resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologytherapy is critical by identifying which antimicrobial combina-
tions give you the highest likelihood of having at least one active
agent against all likely causative pathogens, thereby minimizing
the potential for DAAT [53]. Combination antibiograms offer
signiﬁcant advantages over traditional antibiograms because
they focus on the susceptibility of potential second agents for
combination (e.g. ﬂuoroquinolones and aminoglycosides) in the
setting of resistance to the primary agent (the β-lactam).
Additionally, combination antibiograms can incorporate all
isolates causing a given infection (e.g. 91% of all respiratory
isolates in an ICU are susceptible to either piperacillin-
tazobactam or tobramycin) instead of organism-speciﬁc anti-
biogram information (e.g. 75% of P. aeruginosa are susceptible to
cefepime and 83% are susceptible to tobramycin). By focusing
on all potential causative pathogens in a disease state and the
likelihood that one of the agents is active against all of these
pathogens, combination antibiograms offer an important
method for optimizing appropriate empiric therapy. Further-
more, unit-speciﬁc combination antibiograms have the ability to
differentiate susceptibility proﬁles among various units of an
institution. Pogue et al. used this technique to identify that the
most effective combination regimen in the medical ICU (an anti-
pseudomonal β-lactam plus amikacin) was different from that in
the surgical ICU (an anti-pseudomonal β-lactam plus levo-
ﬂoxacin) at their institution [53]. Data from Nicasio et al.
suggest that combination antibiograms could be ‘taken to the
next level’ by including MIC distributions and pharmacodynamic
dosing recommendations for ventilator-associated pneumonia
[54]. The regimens were selected based on pharmacodynamic
target attainment for P. aeruginosa and the authors were able to
signiﬁcantly increase the rate of appropriate empiric therapy
(72% versus 49%; p 0.007) and decrease the frequency of future
isolation of MDR pathogens (10% versus 27%; p 0.006) with a
dose optimized, pharmacodynamic approach.
Alternatively, Hebert et al. approached the combination
antibiogram in a different way. They created combinations of ESKAPE pathogens predictors
L [95] CRE [75,96,97]
Acinetobacter
baumannii [98,99]
Pseudomonas
aeruginosa [100]
X
X X X
X
X X X
X
X
X
X X
X
X
lactamase-producing Enterobacteriaceae; ICU, intensive care unit; MRSA, methicillin-
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 302–312
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munity isolates from two distinct infectious syndromes: urinary
tract infection, and intra-abdominal infection. By using data only
from the microbiology in these community-acquired disease
states, the authors developed disease-state-speciﬁc antibiotic
recommendations. Not surprisingly, ideal recommendations by
disease state differed (despite similar causative Gram-negative
organisms) and anti-pseudomonal agents were needed to ach-
ieve ~90% activity against causative pathogens. Using this
methodology the authors were able to show that the addition
of a second agent (i.e. largely vancomycin) did not add signiﬁ-
cant additional coverage [55]. These combination antibiogram
data can facilitate an institution’s development of empiric
therapy recommendations for both stable patients, and more
aggressive recommendations for critically ill patients where
time to appropriate therapy has been more strongly linked to
improvement in outcomes. Importantly, however, they do not
take into account patient-speciﬁc factors such as previous
antimicrobial exposures and history of drug-resistant
organisms.
Rapid diagnostics
As rates of drug resistance continue to rise in both Gram-
positive and Gram-negative organisms with overlapping risk
factors, rapid diagnostics become increasingly important. Rapid
diagnostics can be used to both optimize time to appropriate
therapy and also to rapidly ‘de-escalate’ antimicrobials to avoid
unnecessary broad-spectrum antimicrobials (when MDROs are
ruled out). A separate detailed review of the diagnostics chal-
lenges associated with bloodstream infections, is published
along with this review in this theme edition of Clinical Microbi-
ology and Infection [56].
Peptide nucleic acid–ﬂuorescent in situ hybridization (PNA-
FISH) can be an extremely valuable tool for optimizing early
empiric therapy, for example for patients with enterococcal
bloodstream infections [57]. Because of the ability to rapidly
differentiate between Enterococcus faecalis and Enterococcus
faecium, this technology allows clinicians to improve time to
both optimal (ampicillin for E. faecalis) or appropriate (a VRE
active agent for E. faecium) therapy in hospitalized patients.
Investigators at the University of Maryland showed that
coupling this technology with antimicrobial stewardship inter-
vention led to a decrease in time to appropriate therapy for
patients with VRE bacteraemia (1.3 days versus 3.1 days;
p < 0.001) and a subsequent decrease in 30-day mortality (26%
versus 45%; p 0.004) [57].
Microarray technology can provide more detailed informa-
tion regarding both organism identiﬁcation and presence of
resistance genes. Sango et al. were able to decrease time to
appropriate therapy by 31 hours in patients with VREClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectbacteraemia [58]. Although the impact that microarray tech-
nologies can have in patients with VRE infections is impressive,
it offers only a modest improvement over other rapid organism
identiﬁcation technologies (e.g. PNA-FISH) for enterococcal
species, because resistance patterns are largely predictable
based on genus and species information. On the other hand,
microarray technologies have a huge potential to impact time to
appropriate therapy (and, potentially, duration of unnecessary
broad-spectrum exposure) in patients with Gram-negative
bacteraemia where organism identiﬁcation alone can only
have a modest impact on predicting resistance proﬁles for a
given isolate. Although clinical data are lacking on the impact of
microarray blood culture data on outcomes in Gram-negative
bacteraemia, hypothetical analyses have suggested an opportu-
nity to identify certain ESBL (e.g. blaCTX-M) or carbapenemase-
producing organisms 14–33 h sooner than conventional auto-
mated susceptibility testing methodologies [59,60].
Whereas most patients with risk factors for MRSA are
currently started on empiric vancomycin therapy, the true
value of rapid diagnostics can be fully realized with regards to
discontinuing vancomycin when coagulase-negative staphylo-
cocci are identiﬁed or de-escalating to a superior β-lactam
option in the setting of conﬁrmed MSSA. Using the Xpert
MRSA/SA BC system from Cepheid (Sunnyvale, CA, USA),
Parta et al. were able to treat patients with conﬁrmed MSSA
bacteraemia with a superior β-lactam nearly 45 h faster (5.2 h
versus 49.8 h; p 0.007), and decreased total exposure to anti-
MRSA agents in the entire cohort from a mean of 80.7 h in
the control group to a mean of 19.7 h (p 0.003) with use of the
rapid diagnostic test [61]. Similarly, Bauer et al. were able to get
patients with MSSA on targeted therapy 1.7 days earlier with
the use of the same test [62].
In the Gram-negative arena multiple studies have assessed
the impact of mass-spectrometry-based rapid organism identi-
ﬁcation, matrix-assisted laser desorption ionization time-of-
ﬂight (MALDI-TOF), coupled with antibiotic stewardship
intervention on time to appropriate therapy (implementing
active antibiotics), time to optimal therapy (stopping unnec-
essary antibiotics), and outcomes. After implementing MALDI-
TOF in conjunction with a more rapid method for determining
the susceptibilities of organisms, Perez et al. were able to
improve time to appropriate therapy for patients who were on
inappropriate antibiotics at the time of culture positivity. Of 16
patients who were on inappropriate therapy at the time of
positivity, ﬁve (31%) and zero (0%) were still on inappropriate
therapy at 24 and 48 h after positivity in the MALDI-TOF arm
compared with 22/22 (100%) and 15/22 (68%) in the control
arm. Patients in the intervention arm also had a 1.8-day
reduction in length of stay (p 0.01) [63]. Perhaps even more
relevant to this discussion was an additional analysis that theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 302–312
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exclusively in MDR Gram-negative organisms (~75% ESBL, 5%
CRE, 11% P. aeruginosa and 8% A. baumannii). In this analysis the
investigators were able to decrease time to appropriate therapy
(89.7 h versus 32 h; p < 0.001); time to optimal therapy (80.9 h
versus 23.2 h; p < 0.001), and ultimately mortality (21% versus
9%; p 0.01) [64].
These ﬁndings highlight the impact that rapid diagnostics
coupled with stewardship intervention can have in decreasing
DAAT, while limiting unnecessary over-exposure to antibiotics.Summary, conclusions and
recommendationsInfections caused by MDROs have been associated with
devastating outcomes mainly due to DAAT. Unfortunately, risk
factors for ESKAPE pathogens overlap signiﬁcantly, reliable
predicting tools with high performances are not yet available,
and to cover all possible MDROs empirically would require
unrealistic and potentially unsafe routine administration of
broad-spectrum combination regimens. Understanding local
epidemiology is essential in optimizing targeted appropriate
empiric therapy and strategies such as combination antibio-
grams offer signiﬁcant promise as tools that can be used to
optimize empiric therapy regimens. Conversely, however, it is
important that individual patient scenarios and previous anti-
biotic exposures are taken into account and appropriate di-
agnostics are performed. For example, a patient might present
to your institution from a long-term care facility with ‘altered
mental status’ and given the diagnosis of urosepsis. Local sus-
ceptibility data might tell you that patients from this nursing
home have a 30% rate of ESBL-producing Klebsiella pneumoniae
or Escherichia coli. Does this mean that the patient needs an
empiric carbapenem? The answer should incorporate the pa-
tient’s clinical status, balancing the importance of empiric
therapy being active (e.g. if a patient is haemodynamically un-
stable then there is little leeway for providing ineffective ther-
apy) against the pitfalls of overuse of antimicrobials. Waiting in
an otherwise stable patient before prescribing broad-spectrum
agents to cover MDROs when they are unlikely to be present,
is a reasonable approach, unless previous microbiology or
clinical status dictates otherwise. Regardless of the strategy
used, all decisions regarding antimicrobial therapy should be
complemented with aggressive antibiotic stewardship in-
terventions. This might include ensuring that the appropriate
microbiology is obtained (for escalation or de-escalation),
modifying therapy based on rapid diagnostic results, moni-
toring clinical status closely, and watching for unintended
consequences of antimicrobial exposure.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyTransparency declarationThe authors declare that they have no conﬂicts of interest.
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